PLXNA3 and colorectal cancer: Notably, we did not directly assess the predictive value of PLXNA3 in the context of immune checkpoint inhibitor (ICI) therapy, due to the lack of large-scale, colorectal cancer–specific immunotherapy cohorts with available treatment outcome data.